Hospital
Rehoboth Mckinley Christian Health Care Services, INC.
Rehoboth Mckinley Christian Health Care Services, INC. was paid $31.84M by Medicaid between Jan 2018 and Dec 2024, across 263 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoREHOBOTH MCKINLEY CHRISTIAN HEALTH CARE SERVICES, INC.
GALLUP, NM 87301
GALLUP, NM 87301
33aNPI1720084999assigned 06/22/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$31.84M
24GClaims571,540
24DCodes billed263
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 118,366 | $5.15M | |
| 2019 | 94,545 | $4.43M | |
| 2020 | 74,055 | $3.89M | |
| 2021 | 76,019 | $4.09M | |
| 2022 | 74,281 | $4.87M | |
| 2023 | 82,730 | $5.39M | |
| 2024incomplete | 51,544 | $4.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 22,588 | 20,731 | $5.75M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 27,883 | 26,259 | $5.01M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 10,836 | 9,831 | $3.43M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 3,456 | 3,264 | $1.36M |
| G0378 | Hospital observation service, per hour | 2.7% | 2,156 | 1,660 | $859K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 12,982 | 11,041 | $773K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.3% | 4,681 | 4,427 | $739K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.3% | 13,567 | 12,486 | $727K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 5,971 | 4,857 | $696K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 11,170 | 9,420 | $678K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 3,549 | 3,332 | $665K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 11,108 | 9,517 | $632K |
251 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 9,765 | $552K |
| 87631 | 1.7% | 4,188 | $550K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 12,139 | $512K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 4,766 | $485K |
| 80053 | Comprehensive metabolic panel | 1.3% | 31,784 | $430K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 7,522 | $416K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 1,551 | $383K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 982 | $311K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,933 | $274K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,437 | $256K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,025 | $247K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,729 | $220K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,127 | $218K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 662 | $215K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 307 | $204K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,743 | $177K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 775 | $165K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,358 | $157K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 270 | $156K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,527 | $153K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 455 | $146K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,209 | $145K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,184 | $141K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,151 | $128K |
| 83690 | <1% | 12,582 | $105K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,860 | $105K |
| 73610 | <1% | 1,031 | $102K | |
| 84484 | <1% | 8,672 | $101K | |
| 73562 | <1% | 1,043 | $92K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,744 | $90K |
| 95811 | <1% | 158 | $88K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 344 | $86K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 373 | $84K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,904 | $83K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,973 | $80K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,089 | $80K |
| 80306 | <1% | 6,443 | $77K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 117 | $76K |
| 83735 | <1% | 10,774 | $72K | |
| 87040 | <1% | 5,098 | $72K | |
| 83605 | <1% | 5,539 | $70K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 516 | $69K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 528 | $67K |
| 59025 | Fetal non-stress test | <1% | 669 | $66K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 980 | $65K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,685 | $60K |
| 73630 | <1% | 967 | $59K | |
| 81001 | <1% | 12,575 | $58K | |
| 83880 | <1% | 2,310 | $55K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 697 | $54K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,649 | $53K |
| 80061 | Lipid panel | <1% | 3,559 | $51K |
| 70486 | <1% | 301 | $48K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,752 | $47K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,867 | $47K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 492 | $47K |
| 73030 | <1% | 500 | $44K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,114 | $43K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 976 | $43K |
| 82077 | <1% | 1,928 | $41K | |
| 73130 | <1% | 664 | $38K | |
| 96376 | <1% | 2,478 | $37K | |
| 82652 | <1% | 834 | $37K | |
| 81025 | <1% | 4,266 | $36K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,782 | $35K |
| 85007 | <1% | 6,959 | $32K | |
| 82948 | <1% | 7,655 | $31K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 227 | $31K |
| 84703 | <1% | 3,001 | $29K | |
| 85610 | <1% | 5,159 | $27K | |
| 73110 | <1% | 475 | $27K | |
| 96367 | <1% | 744 | $27K | |
| 85027 | <1% | 3,749 | $27K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 793 | $25K |
| 97161 | <1% | 637 | $24K | |
| 97162 | <1% | 492 | $23K | |
| 83655 | <1% | 1,708 | $23K | |
| 73221 | <1% | 95 | $23K | |
| 29125 | <1% | 214 | $23K | |
| 97010 | <1% | 1,657 | $22K | |
| 74018 | <1% | 394 | $22K | |
| 71250 | <1% | 126 | $21K | |
| 85379 | <1% | 1,938 | $21K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 34 | $21K |
| 72100 | <1% | 284 | $20K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 125 | $20K |
| 87430 | <1% | 1,380 | $18K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,077 | $18K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 108 | $18K |
| 86900 | <1% | 1,627 | $17K | |
| 87186 | <1% | 1,614 | $16K | |
| J3490 | Unclassified drugs | <1% | 3,365 | $16K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 694 | $16K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 163 | $15K |
| 74021 | <1% | 183 | $15K | |
| 87081 | <1% | 1,901 | $15K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 73 | $15K |
| 82140 | <1% | 1,026 | $14K | |
| 86592 | <1% | 2,152 | $14K | |
| 87340 | <1% | 1,196 | $14K | |
| 87077 | <1% | 1,754 | $13K | |
| 73564 | <1% | 111 | $13K | |
| 87070 | <1% | 1,289 | $13K | |
| 86850 | <1% | 1,471 | $13K | |
| 86769 | <1% | 452 | $13K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,307 | $12K |
| 82803 | <1% | 600 | $12K | |
| 81003 | <1% | 5,019 | $12K | |
| 84439 | <1% | 1,132 | $12K | |
| 86803 | <1% | 758 | $11K | |
| 97032 | <1% | 873 | $11K | |
| 85730 | <1% | 2,412 | $10K | |
| 86140 | <1% | 1,712 | $10K | |
| 82550 | <1% | 1,374 | $10K | |
| 76801 | <1% | 98 | $9K | |
| 77080 | <1% | 90 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,788 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,686 | $7K |
| 84145 | <1% | 352 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 65 | $7K |
| 94060 | <1% | 67 | $7K | |
| 97035 | <1% | 237 | $7K | |
| 84702 | <1% | 399 | $7K | |
| 87210 | <1% | 1,016 | $7K | |
| 86756 | <1% | 431 | $6K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,942 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,854 | $6K |
| 86901 | <1% | 1,627 | $6K | |
| 86762 | <1% | 434 | $6K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $6K |
| 90715 | <1% | 557 | $6K | |
| 73140 | <1% | 92 | $6K | |
| 99292 | <1% | 34 | $5K | |
| 80329 | <1% | 615 | $5K | |
| 76000 | <1% | 63 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,412 | $5K |
| 84100 | <1% | 1,028 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,665 | $5K |
| 80076 | <1% | 419 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,313 | $4K |
| 84466 | <1% | 343 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 15 | $4K |
| 73080 | <1% | 71 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 54 | $4K |
| 82139 | <1% | 246 | $4K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 645 | $4K |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 177 | $4K |
| 87205 | <1% | 831 | $4K | |
| 82728 | <1% | 282 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,958 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 889 | $3K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,272 | $3K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 214 | $3K |
| 80074 | <1% | 60 | $3K | |
| 82607 | <1% | 184 | $3K | |
| 83540 | <1% | 398 | $3K | |
| 74019 | <1% | 27 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 37 | $3K |
| H0049 | Alcohol and/or drug screening | <1% | 69 | $3K |
| 85651 | <1% | 902 | $3K | |
| 95812 | <1% | 12 | $3K | |
| 88312 | <1% | 28 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 317 | $3K |
| 73090 | <1% | 42 | $2K | |
| 12001 | <1% | 28 | $2K | |
| 80143 | <1% | 111 | $2K | |
| 82150 | <1% | 249 | $2K | |
| 51701 | <1% | 30 | $2K | |
| 80179 | <1% | 96 | $2K | |
| 73502 | <1% | 44 | $2K | |
| 82950 | <1% | 365 | $2K | |
| 86920 | <1% | 16 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,845 | $2K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 239 | $2K |
| 88304 | <1% | 80 | $2K | |
| 71101 | <1% | 27 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 416 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,197 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,026 | $2K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 483 | $2K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 28 | $2K |
| 82009 | <1% | 357 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 14 | $2K |
| 94726 | <1% | 24 | $2K | |
| 93971 | <1% | 24 | $2K | |
| 88738 | <1% | 295 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,339 | $1K |
| 96160 | <1% | 35 | $1K | |
| 80069 | <1% | 106 | $1K | |
| V2632 | Posterior chamber intraocular lens | <1% | 89 | $1K |
| 51798 | <1% | 17 | $872.76 | |
| 87150 | <1% | 29 | $868.58 | |
| 82043 | <1% | 101 | $849.95 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 188 | $830.18 |
| 81015 | <1% | 394 | $829.97 | |
| 82105 | <1% | 39 | $765.91 | |
| 82951 | <1% | 55 | $761.33 | |
| 82570 | <1% | 113 | $736.53 | |
| 73590 | <1% | 14 | $709.27 | |
| 94729 | <1% | 24 | $596.07 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $588.82 |
| 94760 | <1% | 921 | $586.05 | |
| 97164 | <1% | 19 | $537.03 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 638 | $530.28 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 181 | $523.73 |
| 82947 | <1% | 105 | $495.50 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 30 | $487.11 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 548 | $457.36 |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 113 | $363.14 |
| 82746 | <1% | 27 | $361.96 | |
| 84460 | <1% | 56 | $357.82 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 433 | $352.64 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 137 | $340.83 |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | <1% | 52 | $317.35 |
| 85018 | <1% | 96 | $316.80 | |
| 86787 | <1% | 25 | $295.63 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 493 | $291.59 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 29 | $268.59 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 148 | $265.79 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 433 | $255.37 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 58 | $249.32 |
| 84153 | <1% | 12 | $232.75 | |
| 84481 | <1% | 13 | $224.80 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 91 | $200.18 |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 26 | $197.61 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 15 | $190.23 |
| 83615 | <1% | 46 | $181.49 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 80 | $169.87 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 29 | $138.84 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 14 | $134.60 |
| 36416 | <1% | 262 | $116.56 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 98 | $109.38 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 63 | $103.96 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 85 | $92.07 |
| J1815 | Injection, insulin, per 5 units | <1% | 281 | $91.39 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 122 | $90.38 |
| 82272 | <1% | 25 | $89.35 | |
| 82270 | <1% | 33 | $87.56 | |
| 84450 | <1% | 14 | $86.82 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 14 | $63.03 |
| 84550 | <1% | 13 | $58.30 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 303 | $46.86 |
| 82962 | <1% | 12 | $40.51 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 137 | $34.97 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 97 | $27.47 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 59 | $19.28 |
| C9399 | Unclassified drugs or biologicals | <1% | 22 | $6.87 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 180 | $0.93 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 181 | $0.84 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 46 | $0.15 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 47 | $0.15 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILLIS, WAYNE (CEO)
Parent organizationMCKINLEY CHRISTIAN HEALTH CARE SERVICES INC
| Provider | Location | Paid |
|---|---|---|
| Rehoboth Mckinley Christian Health Care Services, INC | Gallup, NM | $9.87M |
| Rehoboth Mckinley Christian Health Care Services, INC | Gallup, NM | $999K |
| Rehoboth Mckinley Christian Health Care Services, INC | Gallup, NM | $527K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.